

GCP Audit Certificate

Issued by: SAKK Quality Assurance & Regulatory Affairs

Sponsor of trials: Swiss Group for Clinical Cancer Research

Scope of Audit: Site selection audit to evaluate the suitability of the
Klinische Forschung Onkologie, Kantonsspital
Graubünden for SAKK Phase I first in human (FIH) trials.

Audit Type: Phase I site selection routine requalification audit

Audited organization: Prof. Dr. med. Roger von Moos
Klinische Forschung Onkologie
Kantonsspital Graubünden
Loestrasse 170
7000 Chur

Auditor: Dr. Britta Tschanz, Manager QA, SAKK Coordination
Center, Effingerstrasse 33, 3008 Bern
Dr. Peter Durrer, Head QA & RA, SAKK Coordination
Center, Effingerstrasse 33, 3008 Bern

Date of initial qualification for phase I (FIH): June 5, 2015

Date of Audit: August 22, 2018

Final Report Issue Date: November 08, 2018

Conclusion: The SAKK considers the site Klinische Forschung
Onkologie, Kantonsspital Graubünden as suitable to
conduct SAKK FIH trials. Regular routine audits will further
verify and confirm the compliance of the site.

Bern, 08.11.2018



Dr. Peter Durrer
Head QA & RA
SAKK



Dr. Peter Brauchli
CEO
SAKK